NeoGenomics Announces Board Changes
Ticker: NEO · Form: 8-K · Filed: Aug 8, 2025 · CIK: 1077183
Sentiment: neutral
Topics: board-changes, management
Related Tickers: NEO
TL;DR
NeoGenomics board shakeup: Rothberg out, Halbert in.
AI Summary
On August 5, 2025, NeoGenomics, Inc. announced the departure of Director Dr. Jonathan R. Rothberg and the election of new Director Dr. David J. Halbert. The company also appointed Dr. Halbert as a member of the Nominating and Corporate Governance Committee and the Compensation Committee. These changes were effective immediately.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing reports routine board changes and appointments, which typically carry low immediate risk.
Key Players & Entities
- NeoGenomics, Inc. (company) — Registrant
- Dr. Jonathan R. Rothberg (person) — Departing Director
- Dr. David J. Halbert (person) — Newly Elected Director
- August 5, 2025 (date) — Effective date of changes
FAQ
Who has departed from the NeoGenomics board of directors?
Dr. Jonathan R. Rothberg has departed from the NeoGenomics board of directors.
Who has been elected as a new director to the NeoGenomics board?
Dr. David J. Halbert has been elected as a new director to the NeoGenomics board.
What committees has Dr. David J. Halbert been appointed to?
Dr. David J. Halbert has been appointed to the Nominating and Corporate Governance Committee and the Compensation Committee.
When were these board changes effective?
These board changes were effective as of August 5, 2025.
What is NeoGenomics, Inc.'s state of incorporation?
NeoGenomics, Inc. is incorporated in Nevada.
Filing Stats: 418 words · 2 min read · ~1 pages · Grade level 12.3 · Accepted 2025-08-08 16:03:26
Key Financial Figures
- $0.001 — ch registered: Common Stock, par value $0.001 per share NEO The Nasdaq Stock Market L
Filing Documents
- neo-20250805.htm (8-K) — 24KB
- 0001077183-25-000162.txt ( ) — 138KB
- neo-20250805.xsd (EX-101.SCH) — 2KB
- neo-20250805_lab.xml (EX-101.LAB) — 22KB
- neo-20250805_pre.xml (EX-101.PRE) — 13KB
- neo-20250805_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEOGENOMICS, INC. Date: August 8, 2025 By: /s/ Alicia C. Olivo Alicia C. Olivo EVP, General Counsel & Business Development and Corporate Secretary